These observations argue for a significant contributory role for AKT signaling in ALL growth, and lend support to our findings that PI3K signaling is a relevant antileukemic target not only in BCR-ABL positive leukemias, but also in other subtypes of ALL. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.